

## DATA AND ANALYSES

### Comparison 1. Acupoint P6 stimulation versus sham

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nausea	27		Risk Ratio (IV, Random, 95% CI)	Subtotals only
1.1 All trials	27	2962	Risk Ratio (IV, Random, 95% CI)	0.71 [0.61, 0.83]
1.2 Adequate sequence generation	16	1899	Risk Ratio (IV, Random, 95% CI)	0.68 [0.56, 0.84]
1.3 Unclear or inadequate adequate sequence generation	11	1063	Risk Ratio (IV, Random, 95% CI)	0.77 [0.61, 0.97]
1.4 Adequate allocation concealment	4	529	Risk Ratio (IV, Random, 95% CI)	0.75 [0.51, 1.10]
1.5 Unclear or inadequate allocation concealment	23	2433	Risk Ratio (IV, Random, 95% CI)	0.70 [0.59, 0.84]
1.6 Adequate blinding of outcome assessor	23	2609	Risk Ratio (IV, Random, 95% CI)	0.69 [0.58, 0.82]
1.7 Unclear or inadequate blinding of outcome assessor	4	353	Risk Ratio (IV, Random, 95% CI)	0.89 [0.69, 1.14]
1.8 Free of selective reporting	19	2414	Risk Ratio (IV, Random, 95% CI)	0.69 [0.57, 0.84]
1.9 Unclear or not free of selective reporting	8	548	Risk Ratio (IV, Random, 95% CI)	0.78 [0.59, 1.02]
1.10 Trials with control event rate less than or equal to 20%	3	354	Risk Ratio (IV, Random, 95% CI)	0.86 [0.51, 1.42]
1.11 Trials with control event rate more than 20%	24	2608	Risk Ratio (IV, Random, 95% CI)	0.71 [0.60, 0.83]
1.12 Children	2	258	Risk Ratio (IV, Random, 95% CI)	0.63 [0.51, 0.80]
1.13 Adults	24	2664	Risk Ratio (IV, Random, 95% CI)	0.74 [0.63, 0.88]
1.14 Invasive P6 stimulation	6	596	Risk Ratio (IV, Random, 95% CI)	0.65 [0.48, 0.89]
1.15 Noninvasive P6 stimulation	21	2366	Risk Ratio (IV, Random, 95% CI)	0.73 [0.61, 0.88]
2 Vomiting	32		Risk Ratio (IV, Random, 95% CI)	Subtotals only
2.1 All trials	32	3385	Risk Ratio (IV, Random, 95% CI)	0.70 [0.59, 0.83]
2.2 Adequate sequence generation	16	1892	Risk Ratio (IV, Random, 95% CI)	0.73 [0.58, 0.91]
2.3 Unclear or inadequate adequate sequence generation	16	1493	Risk Ratio (IV, Random, 95% CI)	0.68 [0.53, 0.87]
2.4 Adequate allocation concealment	4	511	Risk Ratio (IV, Random, 95% CI)	0.72 [0.55, 0.95]
2.5 Unclear or inadequate allocation concealment	28	2874	Risk Ratio (IV, Random, 95% CI)	0.69 [0.57, 0.84]
2.6 Adequate blinding of outcome assessor	26	2907	Risk Ratio (IV, Random, 95% CI)	0.70 [0.58, 0.84]
2.7 Unclear or inadequate blinding of outcome assessor	6	478	Risk Ratio (IV, Random, 95% CI)	0.70 [0.49, 1.00]
2.8 Free of selective reporting	20	2525	Risk Ratio (IV, Random, 95% CI)	0.71 [0.57, 0.89]

2.9 Unclear or not free of selective reporting	12	860	Risk Ratio (IV, Random, 95% CI)	0.68 [0.52, 0.89]
2.10 Trials with control event rate less than or equal to 20%	9	1216	Risk Ratio (IV, Random, 95% CI)	0.86 [0.57, 1.29]
2.11 Trials with control event rate more than 20%	23	2169	Risk Ratio (IV, Random, 95% CI)	0.67 [0.56, 0.81]
2.12 Children	6	542	Risk Ratio (IV, Random, 95% CI)	0.67 [0.46, 0.97]
2.13 Adults	25	2803	Risk Ratio (IV, Random, 95% CI)	0.73 [0.62, 0.86]
2.14 Invasive P6 stimulation	6	596	Risk Ratio (IV, Random, 95% CI)	0.60 [0.43, 0.84]
2.15 Noninvasive P6 stimulation	25	2689	Risk Ratio (IV, Random, 95% CI)	0.71 [0.58, 0.86]
3 Rescue antiemetics	26	2661	Risk Ratio (IV, Random, 95% CI)	0.69 [0.57, 0.83]
3.1 Dimenhydrinate	2	192	Risk Ratio (IV, Random, 95% CI)	0.39 [0.07, 2.16]
3.2 Droperidol	1	64	Risk Ratio (IV, Random, 95% CI)	0.71 [0.22, 2.28]
3.3 Metoclopramide	6	416	Risk Ratio (IV, Random, 95% CI)	0.49 [0.33, 0.73]
3.4 Ondansetron	10	1143	Risk Ratio (IV, Random, 95% CI)	0.68 [0.52, 0.89]
3.5 Prochlorperazine	2	139	Risk Ratio (IV, Random, 95% CI)	0.91 [0.53, 1.54]
3.6 Ondansetron and droperidol	2	341	Risk Ratio (IV, Random, 95% CI)	0.95 [0.67, 1.34]
3.7 Ondansetron and prochlorperazine	1	104	Risk Ratio (IV, Random, 95% CI)	0.33 [0.10, 1.16]
3.8 Dexamethasone	1	50	Risk Ratio (IV, Random, 95% CI)	0.36 [0.15, 0.85]
3.9 Dimenhydrinate and dolasetron	1	212	Risk Ratio (IV, Random, 95% CI)	1.14 [0.43, 3.04]

## Comparison 2. Acupoint P6 stimulation versus antiemetic drug

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Nausea	9		Risk Ratio (IV, Random, 95% CI)	Subtotals only
1.1 Ondansetron	6	393	Risk Ratio (IV, Random, 95% CI)	0.84 [0.61, 1.15]
1.2 Metoclopramide	1	62	Risk Ratio (IV, Random, 95% CI)	0.25 [0.06, 1.08]
1.3 Prochlorperazine	0	0	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.4 Cyclizine	1	62	Risk Ratio (IV, Random, 95% CI)	0.5 [0.14, 1.82]
1.5 Droperidol	2	143	Risk Ratio (IV, Random, 95% CI)	1.02 [0.47, 2.19]
1.6 All antiemetics combined	9	660	Risk Ratio (IV, Random, 95% CI)	0.82 [0.60, 1.13]
1.7 Adequate sequence generation	6	451	Risk Ratio (IV, Random, 95% CI)	0.92 [0.67, 1.25]
1.8 Unclear or inadequate adequate sequence generation	3	209	Risk Ratio (IV, Random, 95% CI)	0.36 [0.15, 0.83]
1.9 Adequate allocation concealment	2	95	Risk Ratio (IV, Random, 95% CI)	0.91 [0.30, 2.74]
1.10 Unclear allocation concealment	7	565	Risk Ratio (IV, Random, 95% CI)	0.78 [0.59, 1.01]
1.11 Adequate blinding of outcome assessor	6	531	Risk Ratio (IV, Random, 95% CI)	0.75 [0.57, 0.99]
1.12 Unclear or inadequate blinding of outcome assessor	3	129	Risk Ratio (IV, Random, 95% CI)	1.16 [0.53, 2.54]

1.13 Free of selective reporting	6	447	Risk Ratio (IV, Random, 95% CI)	0.80 [0.61, 1.04]
1.14 Unclear or not free of selective reporting	3	213	Risk Ratio (IV, Random, 95% CI)	0.73 [0.22, 2.45]
2 Vomiting	14		Risk Ratio (IV, Random, 95% CI)	Subtotals only
2.1 Ondansetron	6	393	Risk Ratio (IV, Random, 95% CI)	1.00 [0.61, 1.66]
2.2 Metoclopramide	2	142	Risk Ratio (IV, Random, 95% CI)	1.49 [0.56, 3.98]
2.3 Prochlorperazine	2	173	Risk Ratio (IV, Random, 95% CI)	1.15 [0.48, 2.77]
2.4 Cyclizine	1	62	Risk Ratio (IV, Random, 95% CI)	0.67 [0.21, 2.13]
2.5 Droperidol	4	266	Risk Ratio (IV, Random, 95% CI)	0.96 [0.64, 1.43]
2.6 All antiemetics combined	14	1036	Risk Ratio (IV, Random, 95% CI)	1.01 [0.77, 1.31]
2.7 Adequate sequence generation	6	436	Risk Ratio (IV, Random, 95% CI)	1.00 [0.65, 1.53]
2.8 Unclear or inadequate sequence generation	8	600	Risk Ratio (IV, Random, 95% CI)	1.01 [0.72, 1.42]
2.9 Adequate allocation concealment	2	80	Risk Ratio (IV, Random, 95% CI)	1.27 [0.59, 2.75]
2.10 Unclear allocation concealment	12	956	Risk Ratio (IV, Random, 95% CI)	0.97 [0.73, 1.30]
2.11 Adequate blinding of outcome assessor	7	611	Risk Ratio (IV, Random, 95% CI)	0.98 [0.65, 1.47]
2.12 Unclear or inadequate blinding of outcome assessor	7	425	Risk Ratio (IV, Random, 95% CI)	1.03 [0.72, 1.46]
2.13 Free of selective reporting	6	447	Risk Ratio (IV, Random, 95% CI)	0.90 [0.56, 1.46]
2.14 Unclear or not free of selective reporting	8	589	Risk Ratio (IV, Random, 95% CI)	1.06 [0.77, 1.46]
3 Rescue antiemetic	7	527	Risk Ratio (IV, Random, 95% CI)	0.82 [0.59, 1.13]
3.1 Ondansetron	4	316	Risk Ratio (IV, Random, 95% CI)	0.88 [0.60, 1.28]
3.2 Metoclopramide	2	160	Risk Ratio (IV, Random, 95% CI)	0.69 [0.32, 1.46]
3.3 Dexamethasone	1	51	Risk Ratio (IV, Random, 95% CI)	0.69 [0.25, 1.88]